Woodline reports 4.4% stake in Quoin Pharmaceuticals

Woodline Partners LP reports beneficial ownership of 2,785,370 Ordinary Shares of Quoin Pharmaceuticals, Ltd., representing 4.4% of the class based on 63,126,930 Ordinary Shares outstanding as of March 23, 2026.

Rhea-AI Filing Summary

Woodline Partners LP reports beneficial ownership of 2,785,370 Ordinary Shares of Quoin Pharmaceuticals, Ltd., representing 4.4% of the class based on 63,126,930 Ordinary Shares outstanding as of March 23, 2026. The reporting statement notes the holdings are ADS-represented (one ADS = 35 Ordinary Shares) and is filed as an amendment to a Schedule 13G.

Insights

Institutional Ownership Analyst

Woodline reports a 4.4% stake in Quoin Pharmaceuticals.

Woodline Partners LP discloses beneficial ownership of 2,785,370 Ordinary Shares, equal to 4.4% of outstanding shares as of March 23, 2026. The position is reported via ADSs where each ADS represents 35 Ordinary Shares.

The practical implications depend on trading intent and filing category: a Schedule 13G indicates passive/beneficial reporting rather than an active control claim; subsequent filings would clarify any change in intent or control.

Regulatory Compliance Counsel

Filing is an amended Schedule 13G reporting passive ownership; disclosures and attribution are explicit.

The amendment identifies Woodline as the reporting person and the Woodline Fund as the direct holder through ADSs (CUSIP 74907L409). It includes precise vote/dispositive counts: 2,785,370 sole voting and dispositive power entries on the cover page.

Compliance notes: the statement expressly disclaims admission of beneficial ownership for Section 13 purposes and uses the company’s 10-K count to calculate the 4.4% figure.

Key Figures

Beneficial ownership: 2,785,370 shares Percent of class: 4.4% Shares outstanding: 63,126,930 Ordinary Shares +2 more

5 metrics

Beneficial ownership 2,785,370 shares Amount reported as sole voting and dispositive power on cover page

Percent of class 4.4% Calculated using 63,126,930 Ordinary Shares outstanding as of March 23, 2026

Shares outstanding 63,126,930 Ordinary Shares As of March 23, 2026, per company's Form 10-K (fiscal year ended December 31, 2025)

ADS conversion ratio 1 ADS = 35 Ordinary Shares Each ADS represents thirty-five Ordinary Shares as stated in the filing

CUSIP (ADS) 74907L409 CUSIP assigned to the Company's ADSs, quoted on Nasdaq under symbol QNRX

Key Terms

ADS, Schedule 13G/A, Beneficial ownership, CUSIP

4 terms

ADS market

"Each ADS represents thirty-five Ordinary Shares."

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

Schedule 13G/A regulatory

"filed as an amendment to a Schedule 13G reporting passive beneficial ownership."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership regulatory

"Amount beneficially owned: The information required by Item 4(a) is set forth..."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

CUSIP market

"The CUSIP number 74907L409 has been assigned to the ADSs of the Company"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Woodline Partners report in Quoin Pharmaceuticals (QNRX)?

Woodline reports beneficial ownership of 2,785,370 Ordinary Shares, representing 4.4% of the class. This percentage is based on 63,126,930 Ordinary Shares outstanding as of March 23, 2026, per the company’s 2025 Form 10-K.

How are Quoin's Ordinary Shares held by Woodline represented?

The disclosure states the shares are represented by American Depositary Shares (ADSs). Each ADS represents 35 Ordinary Shares, and the ADS CUSIP is 74907L409, quoted on Nasdaq under symbol QNRX.

Does this Schedule 13G/A indicate Woodline seeks control of Quoin Pharmaceuticals?

No. The filing is an amendment to a Schedule 13G, which is typically used for passive investors. The statement also includes a disclaimer that the filing should not be construed as admission of beneficial ownership for Section 13 purposes.

What voting and dispositive powers does Woodline report?

The cover-page disclosure reports 2,785,370 shares as sole voting power and sole dispositive power, with 0 shared voting or dispositive power entries. These figures appear on the cover page rows incorporated into Item 4.

When was this Schedule 13G/A signed and by whom?

The filing is signed by Erin Mullen, General Counsel & Chief Compliance Officer, with a signature date of 05/15/2026. The statement lists Woodline Partners LP as the reporting person and provides its San Francisco business address.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 09:13 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Quoin Pharmaceuticals, Ltd.

(Name of Issuer)

Ordinary Shares, no par value per share

(Title of Class of Securities)

74907L409

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 74907L409

1

Names of Reporting Persons

Woodline Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,785,370.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,785,370.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,785,370.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.4 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quoin Pharmaceuticals, Ltd.
(b)	Address of issuer's principal executive offices: 42127 Pleasant Forest Court, Ashburn, VA 20148-7349
Item 2.
(a)	Name of person filing: This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the ordinary shares, no par value per share ("Ordinary Shares"), of Quoin Pharmaceuticals, Ltd. (the "Company") represented by American Depositary Shares ("ADSs") directly held by the Woodline Fund. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP number 74907L409 has been assigned to the ADSs of the Company, which are quoted on The Nasdaq Capital Market under the symbol "QNRX." Each ADS represents thirty-five Ordinary Shares. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Ordinary Shares reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)	Citizenship: Woodline Partners is a Delaware limited partnership.
(d)	Title of class of securities: Ordinary Shares, no par value per share
(e)	CUSIP No.: 74907L409
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 63,126,930 Ordinary Shares outstanding as of March 23, 2026, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 26, 2026.
(b)	Percent of class: 4.4%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Woodline Partners LP

Signature:	/s/ Erin Mullen
Name/Title:	Erin Mullen, General Counsel & Chief Compliance Officer
Date:	05/15/2026